Delivery of immunoprophylactics in transgenic plants: current status.

摘要: The search for economic alternatives the production of recombinant immunoprophylactics has resulted in concept generating them plants at relatively low cost. Two basic strategies are employed: expression antigens or antibodies transgenic plants, presentation small antigen epitopes on surface genetically modified plant viruses. Both approaches have biologically active that been shown animal studies to protect from development disease symptoms. An especially interesting feature producing vaccines edible parts is potential use as a vehicle oral delivery. Substantial progress made over past few years, and first clinical trials demonstrated this new technology. Future challenges express controlled, high concentrations could be grown locally where they needed, develop easy standardised administration procedures.